Axsome Therapeutics (AXSM) News Today $94.60 -0.86 (-0.90%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Royce & Associates LP Has $2.02 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Royce & Associates LP lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 73.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 22,500 shares of the company's stock after acquiring an additional 9,500 sharesNovember 20 at 3:59 AM | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Rating Increased to Hold at StockNews.comStockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday.November 20 at 3:23 AM | marketbeat.comFirst Turn Management LLC Trims Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)First Turn Management LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 24.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 255,294 shares of the comNovember 19 at 6:16 AM | marketbeat.comHead-To-Head Review: Axsome Therapeutics (NASDAQ:AXSM) versus Neoleukin Therapeutics (NASDAQ:NLTX)November 18 at 3:05 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $116.00November 17, 2024 | americanbankingnews.comLeerink Partnrs Has Optimistic View of AXSM FY2024 EarningsNovember 16, 2024 | americanbankingnews.comWilliam Blair Analysts Decrease Earnings Estimates for AXSMNovember 16, 2024 | americanbankingnews.comLeerink Partnrs Issues Positive Forecast for AXSM EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings peNovember 15, 2024 | marketbeat.comFY2027 Earnings Forecast for AXSM Issued By Leerink PartnrsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at Leerink Partnrs dropped their FY2027 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a research note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now anticipates that tNovember 14, 2024 | marketbeat.comStrong Performance and Growth Potential for Axsome Therapeutics Drives Increased Price TargetNovember 14, 2024 | markets.businessinsider.comWilliam Blair Has Negative Outlook for AXSM Q3 EarningsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Research analysts at William Blair dropped their Q3 2024 EPS estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, November 12th. William Blair analyst M. Minter now expects that the company will post earnings pNovember 14, 2024 | marketbeat.comAxsome Therapeutics price target raised to $175 from $173 at LadenburgNovember 14, 2024 | markets.businessinsider.comAxsome Therapeutics price target raised to $116 from $112 at BairdNovember 13, 2024 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comAxsome Therapeutics price target raised to $118 from $106 at BofANovember 13, 2024 | markets.businessinsider.comAxsome Therapeutics (NASDAQ:AXSM) Given New $116.00 Price Target at Robert W. BairdRobert W. Baird raised their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a research report on Wednesday.November 13, 2024 | marketbeat.comAxsome Therapeutics’ Strong Q3 Growth Amidst Strategic ExpansionsNovember 13, 2024 | markets.businessinsider.comAxsome Therapeutics: Strong Financial Performance and Strategic Growth Drive Buy RatingNovember 13, 2024 | markets.businessinsider.comVersor Investments LP Invests $791,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Versor Investments LP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 8,807 shares of the company's stock, valued at appNovember 13, 2024 | marketbeat.comAxsome Delivers Strong Q3 Revenue BeatNovember 13, 2024 | fool.comAxsome Therapeutics: Strong Performance, Promising Pipeline, and Buy Rating Affirmed by Joseph ThomeNovember 13, 2024 | markets.businessinsider.comAxsome Therapeutics: Strong Revenue Performance and Strategic Growth Initiatives Justify Buy RatingNovember 13, 2024 | markets.businessinsider.comAxsome Therapeutics (AXSM) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comAxsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then SellNovember 12, 2024 | seekingalpha.comAxsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week High - Should You Buy?Axsome Therapeutics (NASDAQ:AXSM) Sets New 12-Month High - Time to Buy?November 12, 2024 | marketbeat.comAxsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | markets.businessinsider.comNeedham & Company LLC Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM)Needham & Company LLC reiterated a "buy" rating and set a $130.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday.November 12, 2024 | marketbeat.comAxsome Therapeutics, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 12, 2024 | seekingalpha.comPositive Outlook for Axsome Therapeutics: Steady Growth in Auvelity Prescriptions and Potential Sales Boost from Alzheimer’s ExpansionNovember 11, 2024 | markets.businessinsider.comStrong Commercial Performance of Auvelity Drives Buy Rating for Axsome TherapeuticsNovember 10, 2024 | markets.businessinsider.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Lifted by Privium Fund Management B.V.Privium Fund Management B.V. increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,232 shares of the companyNovember 10, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLCLindbrook Capital LLC trimmed its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 8.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 64,707 shares of the company's stock after selling 5,619 shares duringNovember 9, 2024 | marketbeat.comAxsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024November 8, 2024 | globenewswire.comAxsome Therapeutics (AXSM) Scheduled to Post Quarterly Earnings on TuesdayAxsome Therapeutics (NASDAQ:AXSM) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=635674)November 5, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by abrdn plcabrdn plc cut its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 72.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,048 shares of the company's stock after selling 28,627 sharesNovember 5, 2024 | marketbeat.comPositive Outlook for Axsome Therapeutics: Auvelity’s Strong Growth and Market Edge Justify Buy RatingNovember 4, 2024 | markets.businessinsider.comBuy Rating for Axsome Therapeutics Driven by Strong Auvelity Sales and Market ExpansionNovember 4, 2024 | markets.businessinsider.comAssenagon Asset Management S.A. Sells 29,486 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Assenagon Asset Management S.A. cut its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 86.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,483 shares of the comNovember 4, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Buy" by BrokeragesShares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have earned an average rating of "Buy" from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Fourteen equities research analysts have rated the stock with a buy recommendation. The averaNovember 1, 2024 | marketbeat.comAxsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024October 29, 2024 | globenewswire.comAxsome Therapeutics Inc (19X.SG)October 27, 2024 | uk.finance.yahoo.comOptimistic Outlook for Axsome Therapeutics’ Auvelity Amid Steady Prescription GrowthOctober 26, 2024 | markets.businessinsider.comValues First Advisors Inc. Purchases Shares of 6,322 Axsome Therapeutics, Inc. (NASDAQ:AXSM)Values First Advisors Inc. purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,322 shares of the company's stock, valuedOctober 25, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Trims Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Hennion & Walsh Asset Management Inc. decreased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 10.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,148 shares of the company's stock after sOctober 24, 2024 | marketbeat.comZacks Research Brokers Reduce Earnings Estimates for AXSMAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at Zacks Research reduced their Q3 2024 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now expects that thOctober 23, 2024 | marketbeat.comMorgan Stanley Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)October 22, 2024 | markets.businessinsider.comStrong Commercial Performance and Growth Potential Drive Buy Rating for Axsome Therapeutics’ AuvelityOctober 21, 2024 | markets.businessinsider.comPositive Buy Recommendation for Axsome Therapeutics Driven by Promising AXS-05 Efficacy in Alzheimer’s AgitationOctober 21, 2024 | markets.businessinsider.com3 Bargain Stocks to Buy in a Market That's Priced for PerfectionOctober 19, 2024 | fool.com Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] AXSM Media Mentions By Week AXSM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.560.46▲Average Medical News Sentiment AXSM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼207▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HRMY News XNCR News TARO News UTHR News VTRS News RPRX News SMMT News GMAB News INSM News RDY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts